Join Growin Stock Community!

諾貝兒6844.TW Overview

TW StockBiotech. & Medical
(No presentation for 6844)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

諾貝兒(6844)Overall Performance

諾貝兒(6844)AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

諾貝兒(6844) PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

諾貝兒(6844)Key Information

諾貝兒(6844)Profile

Norbel Baby Co., Ltd engages in the maternity and baby care products, medical supplies, dietary supplements, and cosmetics in Taiwan. It also sells its products through franchised stores. The company was founded in 1986 and is based in Kaohsiung, Taiwan.

諾貝兒(6844)FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

No related data records

default symbol

6844

諾貝兒

64.40D

1.09%

(0.01)

  • When is 6844's latest earnings report released?

    The most recent financial report for 諾貝兒 (6844) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6844's short-term business performance and financial health. For the latest updates on 6844's earnings releases, visit this page regularly.

  • What is the operating profit of 6844?

    According to the latest financial report, 諾貝兒 (6844) reported an Operating Profit of 11.75M with an Operating Margin of 1.38% this period, representing a decline of 57.82% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6844's revenue growth?

    In the latest financial report, 諾貝兒 (6844) announced revenue of 849.27M, with a Year-Over-Year growth rate of 0.4%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6844 have?

    At the end of the period, 諾貝兒 (6844) held Total Cash and Cash Equivalents of 460.5M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6844 go with three margins increasing?

    In the latest report, 諾貝兒 (6844) achieved the “three margins increasing” benchmark, with a gross margin of 34.42%%, operating margin of 1.38%%, and net margin of 1.55%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6844's profit trajectory and future growth potential.

  • Is 6844's EPS continuing to grow?

    According to the past four quarterly reports, 諾貝兒 (6844)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.35. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6844?

    諾貝兒 (6844)'s Free Cash Flow (FCF) for the period is 78.19M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 8.46% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.